Insulet (PODD) Announces Enrollment of First Patient in Omnipod Horizon System Study
- AT&T (T) to Acquire Time Warner (TWX) for $107.50/Share
- Rockwell Collins (COL) to Acquire B/E Aerospace (BEAV) for $6.4B
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Insulet Corporation (Nasdaq: PODD) announced the first patient has completed the feasibility study of the Omnipod Horizon™ Automated Glucose Control System (Omnipod Horizon System). The full study will evaluate the use of a personal Model Predictive Control algorithm with the Omnipod platform in 20 adults with type 1 diabetes and is taking place in a clinical research center setting to gather data to be used to evolve the algorithm in subsequent studies leading to FDA submission.
“We are very excited to be participating in Insulet’s artificial pancreas clinical trials,” said Jordan Pinsker, M.D., senior research physician at William Sansum Diabetes Center. “Working with Professor Francis J. Doyle III and Dr. Eyal Dassau, Sansum played a major role in the development of the original UC Santa Barbara Artificial Pancreas algorithm that Insulet acquired. We look forward to contributing to the clinical and development pathway as Insulet takes this promising technology to a commercial product.”
The Omnipod Horizon System will combine best-in-class technologies into one integrated system consisting of an on-body Omnipod tubeless pump, the latest Dexcom continuous glucose monitoring (CGM) technology, a modified version of Insulet’s handheld controller and state-of-the-art security system architecture. Insulet’s Omnipod Horizon System is unique in that the algorithm looks toward the future horizon of blood glucose levels, reacting quickly and efficiently to adjust insulin delivery to optimize outcomes for each user. The system will provide the same proven lifestyle benefits as the current Omnipod System, such as the discreet, reliable, tubeless form factor and up to three days of non-stop insulin delivery to make it easy to stay connected and avoid disruption of insulin delivery during routine activities like exercising and bathing.
“Our new Omnipod Horizon System is designed to deliver not only improved clinical outcomes, but the greatly desired improvement in quality of life for those living with insulin-dependent diabetes,” said Patrick Sullivan, President and Chief Executive Officer. “With the first clinical study of our innovative artificial pancreas underway, we have taken another important step in fulfilling our mission to improve the lives of people with diabetes.”
Additional trial details, including enrollment information, can be found at ClinicalTrials.gov.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- J2 Global (JCOM) Unit Enters Agreement to Acquire Everyday Health (EVDY) in $465M Deal
- Bristol-Myers Squibb (BMY) Announces FDA Acceptance of Opdivo sBLA as Treatment for Adv. Bladder Cancer
- Overseas Shipholding Group (OSG) Approves Previously Announced Spin-Off
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!